- Home
- INVH vs BIIB Comparison
INVH vs BIIB Comparison
Compare INVH & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVH
- BIIB
- Stock Information
- Founded
- INVH 2012
- BIIB 1978
- Country
- INVH United States
- BIIB United States
- Employees
- INVH N/A
- BIIB N/A
- Industry
- INVH Real Estate
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- INVH Finance
- BIIB Health Care
- Exchange
- INVH Nasdaq
- BIIB Nasdaq
- Market Cap
- INVH 19.1B
- BIIB 20.6B
- IPO Year
- INVH 2017
- BIIB 1991
- Fundamental
- Price
- INVH $31.92
- BIIB $140.60
- Analyst Decision
- INVH Buy
- BIIB Buy
- Analyst Count
- INVH 17
- BIIB 27
- Target Price
- INVH $37.88
- BIIB $220.50
- AVG Volume (30 Days)
- INVH 2.4M
- BIIB 1.6M
- Earning Date
- INVH 02-26-2025
- BIIB 02-12-2025
- Dividend Yield
- INVH 3.64%
- BIIB N/A
- EPS Growth
- INVH N/A
- BIIB 40.28
- EPS
- INVH 0.72
- BIIB 11.18
- Revenue
- INVH $2,554,563,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- INVH N/A
- BIIB N/A
- Revenue Next Year
- INVH $4.25
- BIIB N/A
- P/E Ratio
- INVH $44.43
- BIIB $12.58
- Revenue Growth
- INVH 7.65
- BIIB N/A
- 52 Week Low
- INVH $30.13
- BIIB $128.51
- 52 Week High
- INVH $37.80
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- INVH 54.86
- BIIB 44.88
- Support Level
- INVH $31.32
- BIIB $135.02
- Resistance Level
- INVH $32.31
- BIIB $141.69
- Average True Range (ATR)
- INVH 0.54
- BIIB 4.00
- MACD
- INVH 0.11
- BIIB 0.04
- Stochastic Oscillator
- INVH 76.90
- BIIB 59.44
About INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of nearly 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 16 target markets that feature high employment and household formation growth with almost 70% of the portfolio in the Western U.S. and Florida; 15 of the 16 markets featuring average rents lower than homeownership costs.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.